the neoadjuvant and adjuvant situation, but publications regarding PET or PET/CT for therapy response assessment in melanoma patients are very limited.
With the ongoing development of postprocessing software for PET/CT examinations, it is now possible to routinely assess several semiquantitative parameters such as standard uptake value (SUV) and total lesion glycolysis (TLG) which may -similar to the S-100B tumor marker -reflect the tumor burden [19] .
The aim of this study was to compare the value of the tumor marker S-100B and FDG-PET/CT in patients treated for melanoma metastases by comparing the values of S-100B with PET/CT findings including measurements of TLG and maximum SUV (SUV max. ) before and after therapy.
Materials and Methods

Patients
Our institution is a teaching and tertiary-care hospital and a major referral site for patients with malignant melanoma. Retrospectively, out of 210 in-house patients with high-risk melanoma imaged with PET/CT at our institution, 41 (22 female, 19 male; mean age 57.5 years, range 25-82 years) were identified who fulfilled the following criteria: (1) diagnosis of melanoma with histologically or cytologically proven lymph node, in-transit or distant metastases; (2) availability of S-100B measurements before and after therapy; (3) FDG-PET/CT performed before and after therapy synchronously with the S-100B measurements, and (4) treatment of the metastases between the two PET/CT scans and S-100B measurements. We received approval from our institutional review board to undertake this study.
Determination of S-100B
The determination of S-100B was done with a commercially available immunoassay kit (Sangtec 100 ELISA, Dia Sorin Inc., Stillwater, N.Mex., USA) according to the instructions of the manufacturer. The normal range of 0.0-0.2 g/l was determined from samples of 100 healthy blood donors.
PET/CT Imaging
All the data were acquired on a combined PET/CT in-line system (Discovery LS or Discovery ST, GE Health Systems, Milwaukee, Wisc., USA). These dedicated systems integrate a PET scanner (GE Advance Nxi, GE Health Systems) with a multislice helical CT (Lightspeed plus or Lightspeed 16; GE Health Systems) and permit the acquisition of coregistered CT and PET images in one session.
Patients fasted for at least 4 h prior to the scanning, which started approximately 60 min (mean 61.4 min, SD 8 5.38) after the injection of 370-400 MBq (mean 382.4, SD 8 10.5) of 18 F-FDG. All patients were tested for a normal glucose level (range 80-120 mg/dl, 4.4-6.7 mmol/l) before scanning. Patients with elevated glucose levels were rescheduled and scanned with normal glucose levels. An oral CT contrast agent (Micropaque Scanner, Guerbet AG, Aulnay-sous-Bois, France) was given 15 min before the injection of 18 F-FDG. Patients were examined in the supine position. No intravenous contrast agent was given. Initially, the CT scan was acquired starting from the level of the head using the following parameters: 40 mAs, 140 kV, 0.5 s/tube rotation, slice thickness 4.25 mm, scan length 867 mm, data acquisition time 22.5 s. The CT scan was acquired during breath holding in the normal expiratory position. In the patients with primary tumors of the lower extremities, scanning of the lower legs was added.
Immediately following the CT image acquisition, a PET emission scan was made with an acquisition time of 3 min/cradle position with a 1-slice overlap in 2-dimensional mode (matrix 128 ! 128). The 8-9 cradle positions starting from the head to the knees resulted in an acquisition time of approximately 24-27 min. In the patients with primary tumors of the lower extremities, scanning of the lower legs was added. The CT data were used for the attenuation correction, and the images were reconstructed using a standard iterative algorithm (OSEM). The acquired images were viewed with a software providing multiplanar reformatted images of PET alone, CT alone and fused PET/CT with linked cursors using a Xeleris workstation (GE Health Systems). PET/CT imaging was performed according to the recently published 'Procedure guideline for tumor imaging with 18 F-FDG PET/CT 1.0' [20] .
Measurement of SUV max. and TLG
The images were reviewed and analyzed by two experienced nuclear-radiology physicians without knowledge of the results of other imaging studies. The PET images and the corresponding CT images of the PET/CT study were analyzed for the presence and nature of focal lesions with an increased 18 F-FDG uptake. For all patients, the attenuation-corrected PET images were analyzed. Lesions were interpreted as metastases if the uptake was higher than that of the surrounding background tissue and thus a focal lesion was clearly depictable. 18 F-FDG uptake in physiological or benign variants as in muscles or pulmonary infiltration was excluded from the analysis.
Semiquantitative analysis of FDG uptake in all suspicious lesions was performed by measuring the SUV max. . In our institution, SUV is corrected for lean body mass (LBM). A personal scale (Tanita, model 2001; Tanita, Tokyo, Japan) with an integrated foot-to-foot bioelectric impedance analyzer was used to determine the LBM of the patients. The manufacturer supplied equations for this model incorporating sex, mass, height and a measured impedance value to determine the percentage of body fat and for the calculation of LBM. By using attenuation-corrected PET data, SUV max. was calculated with the following equation by creating a freehand region of interest over the complete visible lesion on the fused PET/CT image: SUV max.(LBM) = (LBM -C FDG )/ dose where LBM is measured in grams, C FDG is the concentration of 18 F-FDG in becquerels per milliliter, and dose is the injected dose measured in becquerels.
Simultaneously, TLG was determined in every PET/CT examination. TLG is a composite parameter that represents the total lesion glycolysis and thus incorporates both the whole body extent and degree of abnormal FDG uptake which was calculated for each PET/CT data set. A 3-dimensional region of interest was drawn around the lesions, and the TLG was determined automatically by accumulating the SUV of all pixels in the volume. This parameter is subject to some interobserver reproducibility issues; so, as a compromise between accuracy, reproducibility and simplicity, a threshold value was chosen at 1.5 and all SUV values above this, in lesions identified as abnormal, were summed and incorporated as a single value. This SUV threshold was prospectively chosen from experience in prior studies where this value was found to effectively exclude most areas of normal FDG uptake apart from the heart, the bladder and, sometimes, the liver. The PET/CT pairs were also analyzed side by side to further reduce issues of variability in drawing regions of interest in FDG-avid disease where the background SUV max. was 1 1.5.
Therapy Response Assessment with S-100B
In all patients S-100B levels were determined before (S-100B 1) and after treatment (S-100B 2). The change of S-100B levels ( ⌬ S-100B = S-100B 1 -S-100B 2/S-100B 1) was assessed. An increase in S-100B after therapy of 1 25% was determined as progressive disease (PD), an increase of less than 25% or a decrease of less than 25% was determined as stable disease (SD), a decrease of more than 25% was determined as partial response (PR) and a decrease from a pathologically elevated S-100B value to a normal value ( ^ 0.2 g/l) was determined as complete response (CR).
Therapy Response Assessment with PET/CT
According to the calculations of ⌬ S-100B, ⌬ TLG ( ⌬ TLG = TLG 1 -TLG 2/TLG 1) and ⌬ SUV max. ( ⌬ SUV max. = SUV max. 1 -SUV max. 2/SUV max. 1) were calculated. Therapy response assessment with PET/CT was determined with a combination of PET and CT criteria: PD was diagnosed in patients with increasing size and/or FDG uptake ( 1 25%) in the known metastases or if new metastases were detected. SD was diagnosed if there was no significant change ( ! 25%) in size and FDG uptake in the known metastases. PR was diagnosed if the size and FDG uptake of the lesions were more than 25% but FDG uptake higher than 1.5 remained in the metastases. CR was determined as complete disappearance of pathological FDG uptake in the metastases. The size of the lesions was measured on the CT part of the PET/CT. If new FDG-negative pulmonary nodules developed between the baseline and the restaging investigation which were not calcified, this was described as PD due to lung metastases. 
Statistical Analysis
Data were analyzed on a patient basis using SPSS 13 (SPSS Inc.). Correlations between changes in tumor markers and PET/ CT findings were derived using Spearman's rank correlation.
Results
S-100B Compared with SUV max. and TLG
In 15 of 41 patients (37%), S-100B values were not suitable because they were normal before (median 0.1 g/l; mean 0.11 g/l; range 0.0-0.2 g/l) and after (0.06 g/l; 0.1 g/l; 0.0-0.1 g/l) therapy. Four of these patients had lymph node and 11 distant metastases. In 26 patients, S-100B was suitable for therapy response assessment with median values of 0.6 g/l (mean 1.7 g/l; range 0.1-14.3 g/l) before and 0.3 g/l (0.96 g/l; 0.0-7.3 g/l) after therapy. In 4 of these 24 patients, the initial S-100B was normal (0.2 g/l; 0.18 g/l; 0.1-0.2 g/l) and increased to abnormal values after therapy (0.75 g/l; 0.78 g/l; 0.5-1.1 g/l). Four of these patients had regional lymph node metastases, 21 distant metastases and 1 in-transit metastases ( fig. 1-3 ) .
The mean SUV max. was abnormal ( 1 1.5) before therapy in all patients (median 8.9; mean 10.6; range 1.7-58.0). After therapy the median SUV max. was 2.7 (8.9; 1.0-65.7). In 17 patients, the SUV max. was ! 1.5 after therapy.
The mean TLG was measurable in all patients with a median value of 105,829 (mean 544,029; range 3,503-7,389,386) before therapy and was not measurable anymore in 17 patients after therapy. In the remaining 24 patients, the median TLG after therapy was 68,654 (mean 
S-100B Compared with FDG-PET/CT regarding Therapy Response
In 15 (37%) patients, S-100B was not suitable for the comparison because the values were normal before and after therapy although the patients had proven metastases (11 patients with distant metastases and 4 with lymph node metastases). Ten of these patients had CR in PET/CT follow-up after therapy, 4 had PD and 1 patient SD. In 26 patients, behavior of S-100B and PET/CT findings could be compared. Altogether there was an excellent correlation between response assessment with S-100B and PET/ CT (r = 0.923, p ! 0.001). The results of therapy assess- Nine patients had PD, 3 patients PR and 10 patients CR with both methods. In 4 patients there was a discrepancy in the assessment of therapy response. In 2 patients S-100B showed a PR and PET/CT a PD, in 1 patient S-100B showed a CR and PET/CT an SD and in 1 patient S-100B showed SD and PET/CT PD. The details and follow-up of the patients with inconsistent findings are summarized in table 3 revealing that by the next measurement of S-100B 3-4 months later 3/4 patient responses were again in complete agreement with the PET/CT findings. In the other patient, no further S-100B value was obtained. Hence within 3 months of the posttherapy study, there was complete agreement between S-100B and PET/CT in 25/26 cases.
Discussion
Because of the considerable number of patients with proven metastases but normal S-100B values, imaging techniques such as PET/CT are necessary to assess tumor load and response to therapy in metastatic melanoma. However, in the subgroup of patients with an abnormal S-100B prior to therapy, there was an excellent correlation between the change in S-100B and the change in qualitative and semiquantitative PET/CT findings in patients treated for melanoma metastases.
Although the effect of chemotherapy in stage IV melanoma patients is still disappointing, many patients with metastases are included in clinical trials where therapy response has to be assessed [21] . Research on melanoma is ongoing, and promising therapy results have been published recently [22, 23] . As soon as an effective therapy of stage IV melanoma becomes available, the need for accurate therapy response assessment will increase dramat- After 3 months alive with progression ically. The data of Henze et al. [5] support the value of serum S-100B as a clinical marker for monitoring therapy response of metastatic melanoma during systemic therapies. FDG-PET/CT is increasingly used for therapy assessment of different tumors [24, 25] . Current data regarding the therapy assessment of melanoma patients with PET or PET/CT are limited to some case reports showing the effect of limb perfusion therapy [26] . To our knowledge, this is the first study comparing the behavior of S-100B and FDG-PET/CT in the therapy assessment of melanoma patients. The major drawback for the S-100B in our study population was that 15 of the patients with proven metastases (11 with distant metastases, 4 with lymph node metastases) had normal S-100B values before therapy. Patients with lymph node metastases more often show normal or lower S-100B values compared with patients with distant metastases because of the lower tumor burden [27] . In many clinical trials, CT remains the imaging modality of choice for therapy assessment in patients with stage IV melanoma. The big advantage of PET/CT is that this method provides the combination of morphological and metabolic information. A recently published study compared FDG-PET/CT imaging for N and M staging of 250 consecutive melanoma patients with PET alone and CT alone; it showed that the accuracy of PET/CT for M staging was significantly higher than that of PET alone and CT alone (98 vs. 93 and 84%) [27] .
The simplest method for therapy assessment is a visual analysis by comparing the baseline and posttherapy scans. Another possibility is the use of semiquantitative measurements like SUV max. or average SUV. This approach takes a little more time if multiple lesions are present but is highly reproducible. From a theoretical point of view, TLG might be the parameter which represents the 'real' tumor burden because size and FDG uptake of all lesions are assessed. The experience with TLG for therapy response assessment is limited and only a few publications have incorporated this parameter [19, 28] . The disadvantage of the TLG approach is that an arbitrary threshold has to be found which we set in our study to an SUV of 1.5. We found that especially in organs with high background uptake like the liver TLG measurement might be difficult. Nevertheless, the correlation between ⌬ S-100B and ⌬ SUV max. as well as ⌬ TLG was excellent as was the correlation of therapy response assessment between S-100B and PET/CT findings based on visual or SUV max. measurements. This study suggests that the time-consuming measurement of TLG in daily routine is not needed, and, if semiquantitative measurement is felt to be necessary, SUV max. is an easily measured and highly reproducible alternative.
The poor sensitivity of PET in detecting brain metastases is well known due to the high physiological uptake in the normal brain. So in this region MRI is the imaging gold standard in the detection of metastases [29] . In our patients we had 1 case where PET/CT clearly showed progression of distant metastases in the liver and lung but missed new brain metastases developed during systemic therapy which were detected with brain MRI. S-100B falsely indicated a PR with a decrease from 12.6 to 3.1 g/l. This case underlines the fact that additional brain MRI is strongly recommended for complete therapy response assessment especially in patients with cerebral symptoms.
Our study has several limitations. This is a retrospective study and has a selection bias because only patients with available S-100B values and simultaneously performed PET/CT examinations before and after therapy were included. Further limitations are the relatively limited number of patients, a reason why the statistical calculations should be interpreted carefully. So far, we cannot present outcome data because the follow-up time at this time point is not long enough. Also, the group of patients in this study is too inhomogeneous with stage III and stage IV melanomas and different treatments including surgery, radiotherapy and different systemic therapies. In an ongoing study we are investigating S-100B and PET/CT in the therapy response assessment of stage IV melanoma patients by comparing both methods with the outcome of the patients.
Interestingly, in all 4 patients with inconsistent findings, PET/CT showed a poorer therapy response compared with the S-100B assessment. The clinical and imaging follow-up of all these confirmed the results of the PET/CT and showed progression in 3 patients and SD followed by progression in 1 patient. It seems that S-100B has the tendency to underestimate the tumor burden or in other words to overestimate the therapy response in some patients.
Our results suggest that therapy response assessment with S-100B might be sufficient if the value is abnormal before implementation of the therapy, particularly if there is planned frequent measurement of this parameter and where it remains stable or falls. However, when the S-100B shows a progressive increase, a PET/CT scan may be indicated because the location and extent of disease may govern the most appropriate therapy in such cases. Further, the use of other imaging modalities such as MRI may also be necessary for the early detection of brain me-tastases or metastases compromising the spinal canal. So decisions when to use imaging or just S-100B in the assessment of therapy need to be made on a patient-by-patient basis after careful consideration of their clinical status and have to be evaluated in further studies with larger patient numbers.
In conclusion, there is an excellent correlation between the S-100B tumor marker and PET/CT findings regarding therapy response assessment in patients treated for melanoma metastases where the S-100B marker is abnormal. However, in one third of patients with melanoma metastases, the S-100B tumor marker is not suitable for therapy response assessment. In these patients PET/CT should be used as the primary imaging modality. PET/CT has a high accuracy to precisely localize the involved anatomic sites and to find the adequate treatment. The criteria for accurate response assessment with PET/CT have to be defined in prospective studies, but it is clear from our study that the more complex and complicated TLG measurement is no better than the simpler and more reproducible SUV max. measurement.
